Emerging anxiolytics

Bibliography

• DSMIV: Diagnostic and Statistical Manual of Mental Disorders, (4th Edition). (DSMIV). American Psychiatric Association, Washington, DC (1994).
   Google Scholar
• LEPINE JP: Epidemiology, burden, and disability in depression and anxiety. J. Clin. Psychiatry (2001) 62:134-210.
   Google Scholar
• KESSLER RC, USTUN TB: The world mental health (WMH) survey initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). Int. J. Methods Psychiatr. Res. (2004) 13:93-121.
   PubMed Web of Science ®Google Scholar
• Cross-national comparisons of the prevalences and correlates of mental disorders. WHO international consortium in psychiatric epidemiology. Bull. World Health Organ. (2000) 78:413-426.
   PubMed Web of Science ®Google Scholar
• WITTCHEN HU, JACOBI F: Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. (2005) 15:357-376.
   PubMed Web of Science ®Google Scholar
• HETTEMA JM, NEALE MC, KENDLER KS: A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry (2001) 158:1568-1578.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, FOSTER CL, SAUNDERS WB, STANG PE: Social consequences of psychiatric disorders, I: educational attainment. Am. J. Psychiatry (1995) 152:1026-1032.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, BERGLUND PA, FOSTER CL, SAUNDERS WB, STANG PE, WALTERS EE: Social consequences of psychiatric disorders, II: teenage parenthood. Am. J. Psychiatry (1997) 154:1405-1411.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, WALTERS EE, FORTHOFER MS: The social consequences of psychiatric disorders, III: probability of marital stability. Am. J. Psychiatry (1998) 155:1092-1096.
   PubMed Web of Science ®Google Scholar
• ETTNER SL, FRANK RG, KESSLER RC: The impact of psychiatric disorders on labor market outcomes. Ind. Lab. Relations Rev. (1997) 51:64-81.
   Web of Science ®Google Scholar
• WAGHORN G, CHANT D, WHITE P, WHITEFORD H: Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust. NZ J. Psychiatry (2005) 39:55-66.
   PubMed Web of Science ®Google Scholar
• RICE DP, MILLER LS: Health economics and cost implications of anxiety and other mental disorders in the US. Br. J. Psychiatry Suppl. (1998) 34:4-9.
   PubMedGoogle Scholar
• KESSLER RC, GREENBERG PE, MICKELSON KD, MENEADES LM, WANG PS: The effects of chronic medical conditions on work loss and work cutback. J. Occup. Environ. Med. (2001) 43:218-225.
   PubMed Web of Science ®Google Scholar
• TOBIN JM, LEWIS ND: New psychotherapeutic agent, chlordiazepoxide. Use in treatment of anxiety states and related symptoms. JAMA (1960) 174:1242-1249.
   PubMed Web of Science ®Google Scholar
• MCMILLEN BA, MATTHEWS RT, SANGHERA MK, SHEPARD PD, GERMAN DC: Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci. (1983) 3:733-738.
   PubMed Web of Science ®Google Scholar
• RICKELS K, WEISMAN K, NORSTAD N et al.: Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry (1982) 43:81-86.
   PubMed Web of Science ®Google Scholar
• CHESSICK CA, ALLEN MH, THASE M et al.: Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. (2006):3CD006115.
   Google Scholar
• RICKELS K, DOWNING R, SCHWEIZER E, HASSMAN H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry (1993) 50:884-895.
   PubMed Web of Science ®Google Scholar
• DAVIDSON J: Drug therapy of post-traumatic stress disorder. Br. J. Psychiatry (1992):160309-160314.
   Google Scholar
• LIEBOWITZ MR, SCHNEIER F, CAMPEAS R et al.: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch. Gen. Psychiatry (1992) 49:290-300.
   PubMed Web of Science ®Google Scholar
• BANDELOW B, ZOHAR J, HOLLANDER E, KASPER S, MOLLER HJ: World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J. Biol. Psychiatry (2002) 3:171-199.
   PubMedGoogle Scholar
• BALDWIN DS: Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes? CNS Spectr. (2006) 11:34-39.
   PubMedGoogle Scholar
• Management of anxiety disorders. Can. J. Psychiatry (2006) 51:S1-S92.
   Web of Science ®Google Scholar
• BUSTO UE, BREMNER KE, KNIGHT K, TERBRUGGE K, SELLERS EM: Long-term benzodiazepine therapy does not result in brain abnormalities. J. Clin. Psychopharmacol. (2000) 20:2-6.
   PubMed Web of Science ®Google Scholar
• ASHTON H: Benzodiazepine withdrawal: an unfinished story. Br. Med. J. (Clin. Res. Ed.) (1984) 288:1135-1140.
   PubMed Web of Science ®Google Scholar
• RAY WA, FOUGHT RL, DECKER MD: Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am. J. Epidemiol. (1992) 136:873-883.
   PubMed Web of Science ®Google Scholar
• BARBONE F, MCMAHON AD, DAVEY PG et al.: Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 352:1331-1336.
   PubMed Web of Science ®Google Scholar
• MONTEJO-GONZALEZ AL, LLORCA G, IZQUIERDO JA et al.: SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. (1997) 23:176-194.
   PubMed Web of Science ®Google Scholar
• SPIGSET O: Adverse reactions of selective serotonin re-uptake inhibitors: reports from a spontaneous reporting system. Drug Saf. (1999) 20:277-287.
   PubMed Web of Science ®Google Scholar
• BALLENGER JC: Current treatments of the anxiety disorders in adults. Biol. Psychiatry (1999) 46:1579-1594.
   PubMed Web of Science ®Google Scholar
• ROGAN MT, STAUBLI UV, LEDOUX JE: Fear conditioning induces associative long-term potentiation in the amygdala. Nature (1997) 390:604-607.
   PubMed Web of Science ®Google Scholar
• LEDOUX JE, CICCHETTI P, XAGORARIS A, ROMANSKI LM: The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. J. Neurosci. (1990) 10:1062-1069.
   PubMed Web of Science ®Google Scholar
• DAVIS M, RAINNIE D, CASSELL M: Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. (1994) 17:208-214.
   PubMed Web of Science ®Google Scholar
• GORMAN JM, KENT JM, SULLIVAN GM, COPLAN JD: Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry (2000) 157:493-505.
   PubMed Web of Science ®Google Scholar
• SAREEN J, CAMPBELL DW, LESLIE WD et al.: Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol. Psychiatry (2007) 61:396-404.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, STEIN DJ, SHALEV AY, YEHUDA R: Post-traumatic stress disorder: acquisition, recognition, course, and treatment. J. Neuropsychiatry Clin. Neurosci. (2004) 16: 135-147.
   PubMed Web of Science ®Google Scholar
• LAPLANE D, LEVASSEUR M, PILLON B et al.: Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. A neuropsychological, magnetic resonance imaging and positron tomography study. Brain (1989) 112:699-725.
   PubMed Web of Science ®Google Scholar
• WHITESIDE SP, PORT JD, ABRAMOWITZ JS: A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. (2004) 132:69-79.
   PubMed Web of Science ®Google Scholar
• PARKS CL, ROBINSON PS, SIBILLE E, SHENK T, TOTH M: Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. USA (1998) 95:10734-10739.
   PubMed Web of Science ®Google Scholar
• HEISLER LK, CHU HM, BRENNAN TJ et al.: Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl. Acad. Sci. USA (1998) 95:15049-15054.
   PubMed Web of Science ®Google Scholar
• RAMBOZ S, OOSTING R, AMARA DA et al.: Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. USA (1998) 95:14476-14481.
   PubMed Web of Science ®Google Scholar
• GROSS C, SANTARELLI L, BRUNNER D, ZHUANG X, HEN R: Altered fear circuits in 5–HT1A receptor KO mice. Biol. Psychiatry 48:1157-1163.
   PubMed Web of Science ®Google Scholar
• SAUDOU F, AMARA DA, DIERICH A et al.: Enhanced aggressive behavior in mice lacking 5–HT1B receptor. Science 265:1875-1878.
   PubMed Web of Science ®Google Scholar
• ZHUANG X, GROSS C, SANTARELLI L, COMPAN V, TRILLAT AC, HEN R: Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology (1999) 21:S52-S60.
   PubMed Web of Science ®Google Scholar
• LIN D, PARSONS LH: Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze. Pharmacol. Biochem. Behav. (2002) 71:581-587.
   PubMed Web of Science ®Google Scholar
• HOLMES A: Targeted gene mutation approaches to the study of anxiety–like behavior in mice. Neurosci. Biobehav. Rev. (2001) 25:261-273.
   PubMed Web of Science ®Google Scholar
• DUXON MS, KENNETT GA, LIGHTOWLER S, BLACKBURN TP, FONE KC: Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology (1997) 36:601-608.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, BRIGHT F, TRAIL B, BAXTER GS, BLACKBURN TP: Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety. Br. J. Pharmacol. (1996) 117:1443-1448.
   PubMed Web of Science ®Google Scholar
• AZNAVOUR N, ZIMMER L: [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology (2007) 52:695-707.
   PubMed Web of Science ®Google Scholar
• GURGUIS GN, UHDE TW: Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology (1990) 15:217-224.
   PubMed Web of Science ®Google Scholar
• ABELSON JL, GLITZ D, CAMERON OG, LEE MA, BRONZO M, CURTIS GC: Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch. Gen. Psychiatry (1991) 48:157-162.
   PubMed Web of Science ®Google Scholar
• TANCER ME, STEIN MB, BLACK B, UHDE TW: Blunted growth hormone responses to growth hormone-releasing factor and to clonidine in panic disorder. Am. J. Psychiatry (1993) 150:336-337.
   PubMed Web of Science ®Google Scholar
• ATACK JR: The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics. Expert Opin. Investig. Drugs (2005) 14:601-618.
   PubMed Web of Science ®Google Scholar
• EARNHEART JC, SCHWEIZER C, CRESTANI F et al.: GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. (2007) 27:3845-3854.
   PubMed Web of Science ®Google Scholar
• FINN DA, RUTLEDGE-GORMAN MT, CRABBE JC: Genetic animal models of anxiety. Neurogenetics (2003) 3:109-135.
   Google Scholar
• NINAN PT, INSEL TM, COHEN RM, COOK JM, SKOLNICK P, PAUL SM: Benzodiazepine receptor-mediated experimental ‘anxiety’ in primates. Science (1982) 218:1332-1334.
   PubMed Web of Science ®Google Scholar
• GODDARD AW, MASON GF, ALMAI A et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch. Gen. Psychiatry (2001) 58:556-561.
   PubMed Web of Science ®Google Scholar
• TIIHONEN J, KUIKKA J, RÄSÄNEN P et al.: Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol. Psychiatry (1997) 2:463-471.
   PubMed Web of Science ®Google Scholar
• HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Annu. Rev. Neurosci. (1994) 17:31-108.
   PubMed Web of Science ®Google Scholar
• MAREN S, AHARONOV G, STOTE DL, FANSELOW MS: N-methyl-D-aspartate receptors in the basolateral amygdala are required for both acquisition and expression of conditional fear in rats. Behav. Neurosci. (1996) 110:1365-1374.
   PubMed Web of Science ®Google Scholar
• MAREN S: Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Mol. Neurobiol. (1996) 13:1-22.
   PubMed Web of Science ®Google Scholar
• ROGAN MT, STAUBLI UV, LEDOUX JE: AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J. Neurosci. (1997) 17:5928-5935.
   PubMed Web of Science ®Google Scholar
• SAJDYK TJ, SHEKHAR A: Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res. (1997) 764:262-264.
   PubMed Web of Science ®Google Scholar
• SAJDYK TJ, SHEKHAR A: Excitatory amino acid receptor antagonists block the cardiovascular and anxiety responses elicited by γ-aminobutyric acidA receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp. Ther. (1997) 283:969-977.
   PubMed Web of Science ®Google Scholar
• WALKER DL, RATTINER LM, DAVIS M: Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav. Neurosci. (2002) 116:1075-1083.
   PubMed Web of Science ®Google Scholar
• WALKER DL, DAVIS M: The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol. Biochem. Behav. (2002) 71:379-392.
   PubMed Web of Science ®Google Scholar
• MATHEW SJ, COPLAN JD, SCHOEPP DD, SMITH EL, ROSENBLUM LA, GORMAN JM: Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders. CNS Spectr. (2001) 6:555-564.
   PubMedGoogle Scholar
• MÜLLER MB, ZIMMERMANN S, SILLABER I et al.: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. (2003) 10:1100-1117.
   Google Scholar
• LIEBSCH G, LANDGRAF R, ENGELMANN M, LORSCHER P, HOLSBOER F: Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J. Psychiatry Res. (1999) 33:153-163.
   PubMed Web of Science ®Google Scholar
• SMITH MA, DAVIDSON J, RITCHIE JC et al.: The corticotropin-releasing hormone test in patients with post-traumatic stress disorder. Biol. Psychiatry (1989) 26:349-355.
   PubMed Web of Science ®Google Scholar
• ROY-BYRNE PP, UHDE TW, POST RM, GALLUCCI W, CHROUSOS GP, GOLD PW: The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry (1986) 143:896-899.
   PubMed Web of Science ®Google Scholar
• RISBROUGH VB, STEIN MB: Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav. (2006) 50:550-561.
   PubMed Web of Science ®Google Scholar
• SMOLLER JW, ROSENBAUM JF, BIEDERMAN J et al.: Association of a genetic marker at the corticotropin-releasing hormone locus with behavioural inhibition. Biol. Psychiatry (2003) 54:1376-1381.
   PubMed Web of Science ®Google Scholar
• SMOLLER JW, YAMAKI LH, FAGERNESS JA et al.: The corticotropin-releasing hormone gene and behavioural inhibition in children at risk for panic disorder. Biol. Psychiatry (2005) 57:1485-1492.
   PubMed Web of Science ®Google Scholar
• EGASHIRA N, TANOUE A, MATSUDA T et al.: Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behav. Brain Res. (2007) 178:123-127.
   PubMed Web of Science ®Google Scholar
• WERSINGER SR, GINNS EI, O'CARROLL AM, LOLAIT SJ, YOUNG WS III: Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry (2002) 7:975-984.
   PubMed Web of Science ®Google Scholar
• LANDGRAF R, GERSTBERGER R, MONTKOWSKI A et al.: V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci. (1995) 15:4250-4258.
   PubMed Web of Science ®Google Scholar
• CARSON WH, KITAGAWA H, NEMEROFF CB: Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol. Bull. (2004) 38(Suppl.):138-145.
   Google Scholar
• SCHMIDT AW, LEBEL LA, HOWARD HR, ZORN SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. (2001) 425:197-201.
   PubMed Web of Science ®Google Scholar
• ZHANG W, PERRY KW, WONG DT et al.: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on noradrenaline and dopamine release in rat prefrontal cortex. Neuropsychopharmacology (2000) 23:250-262.
   PubMed Web of Science ®Google Scholar
• BARTZOKIS G, LU PH, TURNER J, MINTZ J, SAUNDERS CS: Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder. Biol. Psychiatry (2005) 57:474-479.
   PubMed Web of Science ®Google Scholar
• PADALA PR, MADISON J, MONNAHAN M et al.: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int. Clin. Psychopharmacol. (2006) 21:275-280.
   PubMed Web of Science ®Google Scholar
• SIMON NM, HOGE EA, FISCHMANN D et al.: An open-label trial of risperidone augmentation for refractory anxiety disorders. J. Clin. Psychiatry (2006) 67:381-385.
   PubMed Web of Science ®Google Scholar
• BURRIS KD, MOLSKI TF, XU C et al.: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. (2002) 302:381-389.
   PubMed Web of Science ®Google Scholar
• WILNER KD, ANZIANO RJ, JOHNSON AC, MICELI JJ, FRICKE JR, TITUS CK: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J. Clin. Psychopharmacol. (2002) 22:206-210.
   PubMed Web of Science ®Google Scholar
• MOHR N, VYTHILINGUM B, EMSLEY RA, STEIN DJ: Quetiapine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2002) 17:37-40.
   PubMed Web of Science ®Google Scholar
• DELL'OSSO B, MUNDO E, ALTAMURA AC: Quetiapine augmentation of selective serotonin re-uptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectr. (2006) 11:879-883.
   PubMed Web of Science ®Google Scholar
• IPSER JC, CAREY P, DHANSAY Y, FAKIER N, SEEDAT S, STEIN DJ: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst. Rev. (2006) 4:CD005473.
   PubMedGoogle Scholar
• DENYS D, DE GEUS F, VAN MEGEN HJ, WESTENBERG HG: A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin re-uptake inhibitors. J. Clin. Psychiatry (2004) 65:1040-1048.
   PubMed Web of Science ®Google Scholar
• SCHMITT U, HIEMKE C: Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav. Pharmacol. (1999) 10:131-137.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry (2003) 64:1245-1249.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ TL: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol. Bull. (2002) 36:53-57.
   PubMedGoogle Scholar
• SCHALLER JL, THOMAS J, RAWLINGS D: Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed (2004) 6:8.
   PubMedGoogle Scholar
• MONTGOMERY SA, TOBIAS K, ZORNBERG GL, KASPER S, PANDE AC: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry (2006) 67:771-782.
   PubMed Web of Science ®Google Scholar
• RICKELS K, POLLACK MH, FELTNER DE et al.: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry (2005) 62:1022-1030.
   PubMed Web of Science ®Google Scholar
• WALKER DL, RESSLER KJ, LU KT, DAVIS M: Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. (2002) 22:2343-2351.
   PubMed Web of Science ®Google Scholar
• LEDGERWOOD L, RICHARDSON R, CRANNEY J: Effects of d-cycloserine on extinction of conditioned freezing. Behav. Neurosci. (2003) 117:341-349.
   PubMed Web of Science ®Google Scholar
• DAVIS M, RESSLER K, ROTHBAUM BO, RICHARDSON R: Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry (2006) 60:369-375.
   PubMed Web of Science ®Google Scholar
• RESSLER KJ, ROTHBAUM BO, TANNENBAUM L et al.: Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry (2004) 61:1136-1144.
   PubMed Web of Science ®Google Scholar
• HOFMANN SG, POLLACK MH, OTTO MW: Augmentation treatment of psychotherapy for anxiety disorders with d-cycloserine. CNS Drug Rev. (2006) 12:208-217.
   PubMedGoogle Scholar
• HOFMANN SG, MEURET AE, SMITS JA et al.: Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry (2006) 63:298-304.
   PubMed Web of Science ®Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. (1993) 73:229-308.
   PubMed Web of Science ®Google Scholar
• RUPNIAK NM, CARLSON EC, HARRISON T et al.: Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology (2000) 39:1413-1421.
   PubMed Web of Science ®Google Scholar
• BILKEI-GORZO A, RACZ I, MICHEL K, ZIMMER A: Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J. Neurosci. (2002) 22:10046-10052.
   PubMed Web of Science ®Google Scholar
• CHEETA S, TUCCI S, SANDHU J, WILLIAMS AR, RUPNIAK NM, FILE SE: Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res. (2001) 915:170-175.
   PubMed Web of Science ®Google Scholar
• VASSOUT A, VEENSTRA S, HAUSER K et al.: NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul. Pept. (2000) 96:7-16.
   PubMed Web of Science ®Google Scholar
• GAVIOLI EC, CANTERAS NS, DE LIMA TC: Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. Neuroreport (1999) 10:3399-3403.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640-1645.
   PubMed Web of Science ®Google Scholar
• KRAMER MS: Update on substance P (NK-1 receptor) antagonists in clinical trials for depression. Neuropeptides (2000) 34:255.
   PubMed Web of Science ®Google Scholar
• FURMARK T, APPEL L, MICHELGARD A et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry (2005) 58:132-142.
   PubMed Web of Science ®Google Scholar
• DUMONT Y, FOURNIER A, ST PIERRE S, QUIRION R: Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands. J. Pharmacol. Exp. Ther. (1995) 272:673-680.
   PubMed Web of Science ®Google Scholar
• SORENSEN G, LINDBERG C, WORTWEIN G, BOLWIG TG, WOLDBYE DP: Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. (2004) 77:723-729.
   PubMed Web of Science ®Google Scholar
• BOULENGER JP, JERABEK I, JOLICOEUR FB, LAVALLEE YJ, LEDUC R, CADIEUX A: Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am. J. Psychiatry (1996) 153:114-116.
   PubMed Web of Science ®Google Scholar
• SWEERTS BW, JARROTT B, LAWRENCE AJ: Expression of preprogalanin mRNA following acute and chronic restraint stress in brains of normotensive and hypertensive rats. Brain Res. Mol. Brain Res. (1999) 69:113-123.
   PubMedGoogle Scholar
• HOLMES A, KINNEY JW, WRENN CC et al.: Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology (2003) 28:1031-1044.
   PubMed Web of Science ®Google Scholar
• PITMAN RK, SANDERS KM, ZUSMAN RM et al.: Pilot study of secondary prevention of post-traumatic stress disorder with propranolol. Biol. Psychiatry (2002) 51:189-192.
   PubMed Web of Science ®Google Scholar
• VAIVA G, DUCROCQ F, JEZEQUEL K et al.: Immediate treatment with propranolol decreases post-traumatic stress disorder two months after trauma. Biol. Psychiatry (2003) 54:947-949.
   PubMed Web of Science ®Google Scholar